AGIOS PHARM
NASDAQ: AGIO (Agios Pharmaceuticals, Inc.)
Kemas kini terakhir: 1 jam lalu33.32
-0.96 (-2.80%)
| Penutupan Terdahulu | 34.28 |
| Jumlah Dagangan | 519,739 |
| Harga / Jualan (P/S) | 20.46 |
| Harga / Buku (P/B) | 1.99 |
| Julat 52 Minggu |
| Margin Keuntungan | 1,798.26% |
| Margin Operasi (TTM) | -1,221.97% |
| EPS Cair (TTM) | 11.54 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.61% |
| Nisbah Semasa (MRQ) | 18.50 |
| Aliran Tunai Operasi (OCF TTM) | -401.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -237.66 M |
| Pulangan Atas Aset (ROA TTM) | -22.88% |
| Pulangan Atas Ekuiti (ROE TTM) | 60.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Agios Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.57 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.65% |
| % Dimiliki oleh Institusi | 101.39% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |